Excitingly, work modulating the RAS-RAF-MEK-ERK signaling pathway has led to the recent development of a successful therapeutic for inoperable, symptomatic plexiform neurofibromas in children with NF1. Here, MAP2K7 is linked to plexiform neurofibroma.